WWWenhong Wang

Wenhong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenhong Wang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low Serum LDL-C Is Associated with Poorer Overall Survival and Lipid-Related Molecular Features in Colorectal Cancer

    by Juan Wang, Yifang Hsieh, Wenhong Wang, Jing Xu

    Background/Objectives: We investigated whether preoperative serum low-density lipoprotein cholesterol (LDL-C) is associated with prognosis and midkine (MK; encoded by MDK)-related molecular features in colorectal cancer (CRC). Methods: This exploratory translational study integrated a retrospective cohort of 437 surgically treated patients, CRC-focused public transcriptomic analyses of MDK, independent functional enrichment of STRING-derived MK interactors, and immunohistochemistry in tumors from the lowest and highest LDL-C quartiles (n = 10 per group). Overall survival was analyzed using Cox proportional hazards regression. Results: MDK mRNA expression was elevated in CRC and was associated with adverse clinicopathological features. STRING-derived MK interactors showed significant Gene Ontology enrichment for lipoprotein- and low-density lipoprotein-particle receptor-related functions. KEGG cholesterol metabolism showed nominal enrichment but did not remain significant after multiple-testing correction. In the clinical cohort, each 1 mmol/L increase in LDL-C was independently associated with a lower mortality risk (adjusted HR = 0.612, 95% CI, 0.361–0.998; p = 0.048). Tumors from the lowest LDL-C quartile showed higher MK and c-Fos expression and lower ABCA1 expression than tumors from the highest quartile. Conclusions: Lower preoperative LDL-C was associated with poorer overall survival and with exploratory tissue-level molecular differences in CRC. These independent data layers support an associative, hypothesis-generating framework that requires prospective and mechanistic validation.

  • Open Access

    Cancer Cell Dormancy and Chemotherapy Resistance

    by Jingxian Hu, Wei Zhou, Ying Zhao, Peiran Li, Zhenying Zhao, Wei Wang, Wenhong Wang, Yijia Wang

    Cancer cell dormancy is associated with tumor recurrence and metastasis. Chemotherapy usually induces dormancy as external pressure on the tumor. Dormant cells have considerable resistance to antitumor drugs, although they are not harmful to the host if they do not wake up. Chemotherapy induces a dormant phenotype through remodeling of the tumor microenvironment and alteration of intracellular signaling networks. Multiple adaptive mechanisms that confer drug resistance have been identified in these dormant cells, including the unfolded protein response to endoplasmic reticulum stress, metabolic reprogramming favoring oxidative phosphorylation to avoid damage from oxidative stress, and autophagy to realize the circular utilization of energy. However, dormancy is reversible. The conversion between dormancy and awakening of the tumor during chemotherapy and the recovery period after treatment is modulated by several factors, including the dose and cycle of treatment, and individual differences among patients. The direct elimination of cancer cells or permanent dormancy by chemotherapy predicts favorable outcomes. According to this theory, understanding the mechanisms of cancer dormancy and awakening under chemotherapy and improving prognosis using suitable treatment strategies requires further investigation. This review analyzed studies on cancer cell dormancy and response to chemotherapy to identify potential novel interests for future studies and probable strategies to optimize chemotherapy in clinical trials.


  • Prediction of metachronous liver metastasis in mid-low rectal cancer using quantitative perirectal fat content from high-resolution MRI

    by Jiaming Qin, Wenjin Dong, Fengshu Zhao, Tianqi Liu, Mengxin Chen, Rui Zhang, Yumeng Zhao, Cheng Zhang, Wenhong Wang


  • Open Access

    Association Between Skeletal Muscle Mass and Cardiovascular Risk Factors in Occupational Sedentary Population

    by Yaru Lu, Xiao-He Mm Wang, Jing Mm Li, Wenhong Wang, Shi Zhang, Yaping Mm Huang, Yi Wang, Chun-Jun Li

    Objective: The aims of this study were to determine the association of skeletal muscle mass with three cardiovascular risk factors and explore a simple and clinically feasible indicator for identifying high-risk groups of cardiovascular diseases in occupational sedentary population. Methods: We recruited 7316 occupational sedentary participants older than 18 years from the Health Management Center of Tianjin Union Medical Center. Age-adjusted logistic regression was used to analyze the association between skeletal muscle mass index (SMI) and cardiovascular risk factors. Results: There were significant positive associations between SMI, especially arm SMI, and cardiovascular risk factors in both male and female subjects (odds ratio, 1.28 to 5.02; P < 0.001). Conclusions: Our findings suggest that measurements of skeletal muscle mass, particularly in the arms, may help identify individuals at high risk for cardiovascular disease in an occupationally sedentary population.


  • The prognostic and clinical value of p53 upregulated modulator of apoptosis expression in solid tumours: a meta-analysis and TCGA data review

    by Weifeng Gao, Zhen Yuan, Xuanzhu Zhao, Shuyuan Wang, Sizhen Lai, Kemin Ni, Yixiang Zhan, Zhaoce Liu, Lina Liu, Ran Xin, et al.

    Previous studies have reported the prognostic value of p53 upregulated modulator of apoptosis (PUMA) in numerous human tumours, but the conclusions have not been consistent. Therefore, this meta-analysis and the Cancer Genome Atlas (TCGA) data analysis were performed to estimate the prognostic significance of PUMA in solid tumours. A search was conducted in PubMed, Embase, Web of Science, Cochrane Library and CNKI up to July 21, 2022. In total, 10 studies with 2,207 patients were included. We extracted the overall survival (OS) and disease-free survival (DFS) data. The hazard ratios (HRs) and 95% confidence intervals (95% CI) were adopted for evaluating the association. Decreased PUMA expression was significantly associated with worse OS (HR = 0.54, 95% CI = 0.38-0.78) and worse DFS (HR = 0.54, 95% CI = 0.42-0.70). Subgroup analysis showed that the prognostic role of PUMA for OS was most significant in the digestive system (HR = 0.52, 95% CI = 0.38-0.69). Furthermore, the expression of PUMA was not affected by tumour differentiation or clinical stage, and TCGA dataset analysis confirmed these results. We proved that expression of PUMA may serve as an independent prognostic factor for patients with solid tumours.